Genetic variant of cyclooxygenase-2 in gastric cancer: More inflammation and susceptibility

Ji, Xuanke; Madhurapantula, Sailaja Vatsalya; He, Gui; Wang, Kunyan; Song, Chunhua; Zhang, Jianying

doi:10.3748/wjg.v27.i28.4653

Cited by 19 publications

(10 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since the implementation of lifestyle prevention recommendations such as improvements in the preservation and storage of food, adequate hygienic housing, and the consumption of fresh vegetables and fruits, GC incidence has decreased substantially[ 134 ]. H. pylori eradication has been evaluated as a form of chemoprevention of GC by antimicrobial therapy with additional administration of NSAIDs, such as aspirin[ 135 ]. Chronic inflammatory mediators may serve as potential therapeutic targets for the prevention of GC[ 121 ].…”

Section: Strategies For Population-wide and Targeted Screening Of Mal...mentioning

confidence: 99%

Prevention of malignant digestive system tumors should focus on the control of chronic inflammation

Zhang¹,

Chen²,

Hou³

et al. 2023

World J Gastrointest Oncol

Self Cite

View full text Add to dashboard Cite

Chronic inflammation, through a variety of mechanisms, plays a key role in the occurrence and development of digestive system malignant tumors (DSMTs). In this study, we feature and provide a comprehensive understanding of DSMT prevention strategies based on preventing or controlling chronic inflammation. The development and evaluation of cancer prevention strategies is a longstanding process. Cancer prevention, especially in the early stage of life, should be emphasized throughout the whole life course. Issues such as the time interval for colon cancer screening, the development of direct-acting antiviral drugs for liver cancer, and the Helicobacter pylori vaccine all need to be explored in long-term, large-scale experiments in the future.

show abstract

Section: Strategies For Population-wide and Targeted Screening Of Mal...mentioning

confidence: 99%

Prevention of malignant digestive system tumors should focus on the control of chronic inflammation

Zhang¹,

Chen²,

Hou³

et al. 2023

World J Gastrointest Oncol

Self Cite

View full text Add to dashboard Cite

show abstract

“…The inhibition of COX-2, extensively present in the gastrointestinal tract, reduces prostaglandin E2 production, downregulating inflammation oncogenesis pathways ( 9 ). COX inhibitors, such as aspirin, could have a significant role in inherent conditions, such as familial adenomatous polyposis ( 10 , 11 ). However, most of the current knowledge is focused on colorectal polyps, and few are debated for those located in the upper gastrointestinal system.…”

Section: Prevention Measuresmentioning

confidence: 99%

Editorial: Premalignant conditions in the esophagus and stomach

2022

View full text Add to dashboard Cite

Over the years, the development of minimally invasive procedures, endoscopy and chromoscopy, serum and histologic biomarkers, and epidemiology have allowed early detection, management, and treatment of premalignant lesions, conditions associated with high risk for cancer, and early neoplasms. The earliest management, investigation, and follow-up of premalignant lesions and superficial neoplasms in the esophagus and stomach are essential, as they can further improve the survival rates and reduce local and systemic recurrence by allowing prompt curative interventions. Understanding cancer initiation and progressionSeveral conditions promote a higher risk for the development of esophagogastric cancer. It encompasses Barrett's esophagus, achalasia, atrophic gastritis, esophagitis of varying types (e.g., infectious, drug-induced, eosinophilic, etc.), esophageal stenosis due to ingestion of corrosive agents, polyposis, among others. Each condition promotes a different risk ratio for cancer development (1, 2).Chronic inflammation is a factor that is common for several of these conditions (3). Chronic inflammation may contribute to oncogenesis through several different pathways, including DNA damage, angiogenesis, and deregulation of cellular growth, proliferation, and death (4). See Figure 1.

show abstract

“…Despite a significant decline in incidence over the past decades, gastric cancer (GC) still accounts for most cancer-related fatalities worldwide [1,2]. It is estimated that patients with advanced GC have a 5-year survival rate of less than 10% [3]. Therefore, understanding the molecular basis of GC is critical for improving the prognosis of GC patients.…”

Section: Introductionmentioning

confidence: 99%

PTBP1 drives c-Myc-dependent gastric cancer progression and stemness

Chu

et al. 2023

Br J Cancer

View full text Add to dashboard Cite

Background Gastric cancer (GC) tumorigenesis and treatment failure are caused by cancer stem cells. Polypyrimidine tract binding protein 1 (PTBP1) was shown to be involved in the development of embryonic stem cells and is now being considered as a therapeutic target for tumour progression and stem-cell characteristics. Methods PTBP1 expression in GC samples was detected using tissue microarrays. Proliferation, colony formation, spheroid formation and stem-cell analysis were used to examine PTBP1’s role in tumorigenesis and stem-cell maintenance. In AGS and HGC-27 cells with or without PTBP1 deficiency, ubiquitin-related protein expression and co-precipitation assays were performed. Results We identified that PTBP1 was aberrantly highly expressed and represented a novel prognostic factor in GC patients. PTBP1 maintained the tumorigenic activity and stem-cell characteristics of GC in vitro and in vivo. PTBP1 directly interacts with c-Myc and stabilises its protein levels by preventing its proteasomal degradation. This is mediated by upregulating the ubiquitin-specific proteases USP28 and limiting FBW7-mediated ubiquitination of c-Myc. Moreover, the depletion of PTBP1-caused tumour regression was significantly compromised by exogenous c-Myc expression. Conclusions By preserving the stability of c-Myc through the ubiquitin–proteasome pathway, the oncogene PTBP1 supports stem-cell-like phenotypes of GC and is involved in GC progression.

show abstract

Genetic variant of cyclooxygenase-2 in gastric cancer: More inflammation and susceptibility

Cited by 19 publications

References 83 publications

Prevention of malignant digestive system tumors should focus on the control of chronic inflammation

Prevention of malignant digestive system tumors should focus on the control of chronic inflammation

Editorial: Premalignant conditions in the esophagus and stomach

PTBP1 drives c-Myc-dependent gastric cancer progression and stemness

Contact Info

Product

Resources

About